Landos Biopharma, Inc.
Landos Biopharma, Inc. LABP Peers
See (LABP) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| LABP | $22.93 | +0.57% | 71.7M | -5.73 | -$4.00 | N/A |
| VRTX | $474.28 | +3.24% | 119.8B | -122.40 | -$3.81 | N/A |
| REGN | $549.02 | +2.03% | 58.1B | 13.91 | $39.36 | +0.32% |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $316.25 | -2.43% | 41.4B | -150.43 | -$2.11 | N/A |
| ARGX | $541.68 | -0.80% | 32.9B | 32.85 | $16.39 | N/A |
| BNTX | $110.80 | +0.68% | 26.9B | -29.71 | -$3.76 | N/A |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| RPRX | $35.63 | +0.11% | 20B | 14.49 | $2.45 | +3.02% |
| DNA-WT | $0.27 | -2.76% | 18.7B | N/A | N/A | N/A |
Stock Comparison
LABP vs VRTX Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, VRTX has a market cap of 119.8B. Regarding current trading prices, LABP is priced at $22.93, while VRTX trades at $474.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas VRTX's P/E ratio is -122.40. In terms of profitability, LABP's ROE is -0.55%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, LABP is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs REGN Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, REGN has a market cap of 58.1B. Regarding current trading prices, LABP is priced at $22.93, while REGN trades at $549.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas REGN's P/E ratio is 13.91. In terms of profitability, LABP's ROE is -0.55%, compared to REGN's ROE of +0.15%. Regarding short-term risk, LABP is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs SGEN Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, LABP is priced at $22.93, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas SGEN's P/E ratio is -57.19. In terms of profitability, LABP's ROE is -0.55%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, LABP is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for LABP.
LABP vs ALNY Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, ALNY has a market cap of 41.4B. Regarding current trading prices, LABP is priced at $22.93, while ALNY trades at $316.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas ALNY's P/E ratio is -150.43. In terms of profitability, LABP's ROE is -0.55%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, LABP is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs ARGX Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, ARGX has a market cap of 32.9B. Regarding current trading prices, LABP is priced at $22.93, while ARGX trades at $541.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas ARGX's P/E ratio is 32.85. In terms of profitability, LABP's ROE is -0.55%, compared to ARGX's ROE of +0.23%. Regarding short-term risk, LABP is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs BNTX Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, BNTX has a market cap of 26.9B. Regarding current trading prices, LABP is priced at $22.93, while BNTX trades at $110.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas BNTX's P/E ratio is -29.71. In terms of profitability, LABP's ROE is -0.55%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, LABP is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs BGNE Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, LABP is priced at $22.93, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas BGNE's P/E ratio is -22.55. In terms of profitability, LABP's ROE is -0.55%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, LABP is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs RPRX Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, RPRX has a market cap of 20B. Regarding current trading prices, LABP is priced at $22.93, while RPRX trades at $35.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas RPRX's P/E ratio is 14.49. In terms of profitability, LABP's ROE is -0.55%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, LABP is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs DNA-WT Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, LABP is priced at $22.93, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, LABP's ROE is -0.55%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, LABP is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs SMMT Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, SMMT has a market cap of 17.1B. Regarding current trading prices, LABP is priced at $22.93, while SMMT trades at $23.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas SMMT's P/E ratio is -67.62. In terms of profitability, LABP's ROE is -0.55%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, LABP is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs UTHR Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, UTHR has a market cap of 13.3B. Regarding current trading prices, LABP is priced at $22.93, while UTHR trades at $297.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas UTHR's P/E ratio is 11.73. In terms of profitability, LABP's ROE is -0.55%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, LABP is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs GMAB Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, GMAB has a market cap of 13.2B. Regarding current trading prices, LABP is priced at $22.93, while GMAB trades at $21.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas GMAB's P/E ratio is 12.50. In terms of profitability, LABP's ROE is -0.55%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, LABP is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs INCY Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, INCY has a market cap of 13.1B. Regarding current trading prices, LABP is priced at $22.93, while INCY trades at $68.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas INCY's P/E ratio is 338.45. In terms of profitability, LABP's ROE is -0.55%, compared to INCY's ROE of +0.01%. Regarding short-term risk, LABP is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs KRTX Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, LABP is priced at $22.93, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas KRTX's P/E ratio is -28.09. In terms of profitability, LABP's ROE is -0.55%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, LABP is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for LABP.
LABP vs MRNA Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, MRNA has a market cap of 12.6B. Regarding current trading prices, LABP is priced at $22.93, while MRNA trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas MRNA's P/E ratio is -3.73. In terms of profitability, LABP's ROE is -0.55%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, LABP is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs EXEL Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, EXEL has a market cap of 11.9B. Regarding current trading prices, LABP is priced at $22.93, while EXEL trades at $43.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas EXEL's P/E ratio is 19.86. In terms of profitability, LABP's ROE is -0.55%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, LABP is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs BMRN Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, BMRN has a market cap of 11.1B. Regarding current trading prices, LABP is priced at $22.93, while BMRN trades at $59.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas BMRN's P/E ratio is 21.48. In terms of profitability, LABP's ROE is -0.55%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, LABP is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs ASND Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, ASND has a market cap of 10.1B. Regarding current trading prices, LABP is priced at $22.93, while ASND trades at $175.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas ASND's P/E ratio is -25.23. In terms of profitability, LABP's ROE is -0.55%, compared to ASND's ROE of +1.91%. Regarding short-term risk, LABP is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs RXDX Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, LABP is priced at $22.93, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas RXDX's P/E ratio is -56.47. In terms of profitability, LABP's ROE is -0.55%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, LABP is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for LABP.
LABP vs IMGN Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, LABP is priced at $22.93, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas IMGN's P/E ratio is -111.55. In terms of profitability, LABP's ROE is -0.55%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, LABP is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for LABP.
LABP vs BPMC Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, BPMC has a market cap of 8.3B. Regarding current trading prices, LABP is priced at $22.93, while BPMC trades at $128.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas BPMC's P/E ratio is -51.36. In terms of profitability, LABP's ROE is -0.55%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, LABP is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for LABP.
LABP vs TECH Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, TECH has a market cap of 8.3B. Regarding current trading prices, LABP is priced at $22.93, while TECH trades at $53.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas TECH's P/E ratio is 63.47. In terms of profitability, LABP's ROE is -0.55%, compared to TECH's ROE of +0.06%. Regarding short-term risk, LABP is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs BBIO Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, BBIO has a market cap of 8.2B. Regarding current trading prices, LABP is priced at $22.93, while BBIO trades at $44.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas BBIO's P/E ratio is -12.13. In terms of profitability, LABP's ROE is -0.55%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, LABP is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs CERE Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, LABP is priced at $22.93, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas CERE's P/E ratio is -16.47. In terms of profitability, LABP's ROE is -0.55%, compared to CERE's ROE of -0.43%. Regarding short-term risk, LABP is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for LABP.
LABP vs ROIVW Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, LABP is priced at $22.93, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, LABP's ROE is -0.55%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, LABP is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs ROIV Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, ROIV has a market cap of 7.4B. Regarding current trading prices, LABP is priced at $22.93, while ROIV trades at $11.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas ROIV's P/E ratio is -14.48. In terms of profitability, LABP's ROE is -0.55%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, LABP is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs VRNA Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, VRNA has a market cap of 7.4B. Regarding current trading prices, LABP is priced at $22.93, while VRNA trades at $104.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas VRNA's P/E ratio is -43.43. In terms of profitability, LABP's ROE is -0.55%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, LABP is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for LABP.
LABP vs CORT Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, CORT has a market cap of 7.2B. Regarding current trading prices, LABP is priced at $22.93, while CORT trades at $68.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas CORT's P/E ratio is 59.22. In terms of profitability, LABP's ROE is -0.55%, compared to CORT's ROE of +0.20%. Regarding short-term risk, LABP is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs AMRN Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, AMRN has a market cap of 7B. Regarding current trading prices, LABP is priced at $22.93, while AMRN trades at $16.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas AMRN's P/E ratio is -3.82. In terms of profitability, LABP's ROE is -0.55%, compared to AMRN's ROE of -0.17%. Regarding short-term risk, LABP is less volatile compared to AMRN. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs HALO Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, HALO has a market cap of 6.9B. Regarding current trading prices, LABP is priced at $22.93, while HALO trades at $56.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas HALO's P/E ratio is 14.84. In terms of profitability, LABP's ROE is -0.55%, compared to HALO's ROE of +1.22%. Regarding short-term risk, LABP is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs RVMD Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, RVMD has a market cap of 6.8B. Regarding current trading prices, LABP is priced at $22.93, while RVMD trades at $37.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas RVMD's P/E ratio is -9.09. In terms of profitability, LABP's ROE is -0.55%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, LABP is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs JAZZ Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, JAZZ has a market cap of 6.6B. Regarding current trading prices, LABP is priced at $22.93, while JAZZ trades at $110.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas JAZZ's P/E ratio is 14.83. In terms of profitability, LABP's ROE is -0.55%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, LABP is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs IONS Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, IONS has a market cap of 6.6B. Regarding current trading prices, LABP is priced at $22.93, while IONS trades at $41.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas IONS's P/E ratio is -13.82. In terms of profitability, LABP's ROE is -0.55%, compared to IONS's ROE of -0.92%. Regarding short-term risk, LABP is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs RETA Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, LABP is priced at $22.93, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas RETA's P/E ratio is -66.29. In terms of profitability, LABP's ROE is -0.55%, compared to RETA's ROE of +0.47%. Regarding short-term risk, LABP is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for LABP.
LABP vs MDGL Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, MDGL has a market cap of 6.4B. Regarding current trading prices, LABP is priced at $22.93, while MDGL trades at $299.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas MDGL's P/E ratio is -16.12. In terms of profitability, LABP's ROE is -0.55%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, LABP is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs TGTX Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, TGTX has a market cap of 5.7B. Regarding current trading prices, LABP is priced at $22.93, while TGTX trades at $36.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas TGTX's P/E ratio is 142.44. In terms of profitability, LABP's ROE is -0.55%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, LABP is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs ABCM Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, LABP is priced at $22.93, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, LABP's ROE is -0.55%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, LABP is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for LABP.
LABP vs ISEE Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, LABP is priced at $22.93, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas ISEE's P/E ratio is -22.44. In terms of profitability, LABP's ROE is -0.55%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, LABP is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for LABP.
LABP vs AXSM Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, AXSM has a market cap of 5.3B. Regarding current trading prices, LABP is priced at $22.93, while AXSM trades at $112.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas AXSM's P/E ratio is -18.44. In terms of profitability, LABP's ROE is -0.55%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, LABP is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs TLX Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, TLX has a market cap of 5.3B. Regarding current trading prices, LABP is priced at $22.93, while TLX trades at $16.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas TLX's P/E ratio is 174.11. In terms of profitability, LABP's ROE is -0.55%, compared to TLX's ROE of +0.14%. Regarding short-term risk, LABP is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs NUVL Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, NUVL has a market cap of 5.2B. Regarding current trading prices, LABP is priced at $22.93, while NUVL trades at $80.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas NUVL's P/E ratio is -17.82. In terms of profitability, LABP's ROE is -0.55%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, LABP is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs ALKS Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, ALKS has a market cap of 4.8B. Regarding current trading prices, LABP is priced at $22.93, while ALKS trades at $29.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas ALKS's P/E ratio is 14.00. In terms of profitability, LABP's ROE is -0.55%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, LABP is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs CRSP Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, CRSP has a market cap of 4.7B. Regarding current trading prices, LABP is priced at $22.93, while CRSP trades at $57.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas CRSP's P/E ratio is -12.19. In terms of profitability, LABP's ROE is -0.55%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, LABP is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs ALPN Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, LABP is priced at $22.93, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas ALPN's P/E ratio is -101.52. In terms of profitability, LABP's ROE is -0.55%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, LABP is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for LABP.
LABP vs PCVX Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, PCVX has a market cap of 4.3B. Regarding current trading prices, LABP is priced at $22.93, while PCVX trades at $34.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas PCVX's P/E ratio is -8.37. In terms of profitability, LABP's ROE is -0.55%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, LABP is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs SLNO Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, SLNO has a market cap of 4.3B. Regarding current trading prices, LABP is priced at $22.93, while SLNO trades at $86.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas SLNO's P/E ratio is -17.99. In terms of profitability, LABP's ROE is -0.55%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, LABP is less volatile compared to SLNO. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs ADMA Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, ADMA has a market cap of 4.2B. Regarding current trading prices, LABP is priced at $22.93, while ADMA trades at $18.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas ADMA's P/E ratio is 21.19. In terms of profitability, LABP's ROE is -0.55%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, LABP is less volatile compared to ADMA. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs OPT Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, LABP is priced at $22.93, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas OPT's P/E ratio is -1.52. In terms of profitability, LABP's ROE is -0.55%, compared to OPT's ROE of +2.60%. Regarding short-term risk, LABP is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for LABP.
LABP vs RYTM Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, RYTM has a market cap of 4.1B. Regarding current trading prices, LABP is priced at $22.93, while RYTM trades at $81.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas RYTM's P/E ratio is -23.27. In terms of profitability, LABP's ROE is -0.55%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, LABP is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs KRYS Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, KRYS has a market cap of 4.1B. Regarding current trading prices, LABP is priced at $22.93, while KRYS trades at $144.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas KRYS's P/E ratio is 34.43. In terms of profitability, LABP's ROE is -0.55%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, LABP is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs MRTX Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, LABP is priced at $22.93, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas MRTX's P/E ratio is -4.82. In terms of profitability, LABP's ROE is -0.55%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, LABP is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for LABP.
LABP vs CYTK Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, CYTK has a market cap of 4.1B. Regarding current trading prices, LABP is priced at $22.93, while CYTK trades at $35.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas CYTK's P/E ratio is -6.47. In terms of profitability, LABP's ROE is -0.55%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, LABP is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs AKRO Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, AKRO has a market cap of 4B. Regarding current trading prices, LABP is priced at $22.93, while AKRO trades at $52.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas AKRO's P/E ratio is -13.42. In terms of profitability, LABP's ROE is -0.55%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, LABP is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs MRUS Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, MRUS has a market cap of 3.9B. Regarding current trading prices, LABP is priced at $22.93, while MRUS trades at $53.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas MRUS's P/E ratio is -12.58. In terms of profitability, LABP's ROE is -0.55%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, LABP is less volatile compared to MRUS. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs ZLAB Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, ZLAB has a market cap of 3.9B. Regarding current trading prices, LABP is priced at $22.93, while ZLAB trades at $34.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas ZLAB's P/E ratio is -13.98. In terms of profitability, LABP's ROE is -0.55%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, LABP is less volatile compared to ZLAB. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs PTCT Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, PTCT has a market cap of 3.8B. Regarding current trading prices, LABP is priced at $22.93, while PTCT trades at $47.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas PTCT's P/E ratio is 7.32. In terms of profitability, LABP's ROE is -0.55%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, LABP is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs RYZB Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, LABP is priced at $22.93, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas RYZB's P/E ratio is -57.86. In terms of profitability, LABP's ROE is -0.55%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, LABP is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for LABP.
LABP vs CBAY Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, LABP is priced at $22.93, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas CBAY's P/E ratio is -32.81. In terms of profitability, LABP's ROE is -0.55%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, LABP is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for LABP.
LABP vs RARE Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, RARE has a market cap of 3.7B. Regarding current trading prices, LABP is priced at $22.93, while RARE trades at $41.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas RARE's P/E ratio is -6.76. In terms of profitability, LABP's ROE is -0.55%, compared to RARE's ROE of -1.86%. Regarding short-term risk, LABP is less volatile compared to RARE. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs ACLX Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, ACLX has a market cap of 3.7B. Regarding current trading prices, LABP is priced at $22.93, while ACLX trades at $68.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas ACLX's P/E ratio is -22.25. In terms of profitability, LABP's ROE is -0.55%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, LABP is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs AAPG Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, AAPG has a market cap of 3.6B. Regarding current trading prices, LABP is priced at $22.93, while AAPG trades at $41.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas AAPG's P/E ratio is -55.51. In terms of profitability, LABP's ROE is -0.55%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, LABP is less volatile compared to AAPG. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs SWTX Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, LABP is priced at $22.93, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas SWTX's P/E ratio is -13.78. In terms of profitability, LABP's ROE is -0.55%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, LABP is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for LABP.
LABP vs RNA Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, RNA has a market cap of 3.5B. Regarding current trading prices, LABP is priced at $22.93, while RNA trades at $29.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas RNA's P/E ratio is -9.76. In terms of profitability, LABP's ROE is -0.55%, compared to RNA's ROE of -0.27%. Regarding short-term risk, LABP is less volatile compared to RNA. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs ACAD Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, ACAD has a market cap of 3.5B. Regarding current trading prices, LABP is priced at $22.93, while ACAD trades at $21.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas ACAD's P/E ratio is 15.34. In terms of profitability, LABP's ROE is -0.55%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, LABP is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs LEGN Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, LEGN has a market cap of 3.5B. Regarding current trading prices, LABP is priced at $22.93, while LEGN trades at $37.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas LEGN's P/E ratio is -31.78. In terms of profitability, LABP's ROE is -0.55%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, LABP is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs VKTX Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, VKTX has a market cap of 3.4B. Regarding current trading prices, LABP is priced at $22.93, while VKTX trades at $30.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas VKTX's P/E ratio is -26.03. In terms of profitability, LABP's ROE is -0.55%, compared to VKTX's ROE of -0.14%. Regarding short-term risk, LABP is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs SRRK Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, SRRK has a market cap of 3.3B. Regarding current trading prices, LABP is priced at $22.93, while SRRK trades at $35.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas SRRK's P/E ratio is -13.43. In terms of profitability, LABP's ROE is -0.55%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, LABP is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs MTSR Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, MTSR has a market cap of 3.2B. Regarding current trading prices, LABP is priced at $22.93, while MTSR trades at $32.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas MTSR's P/E ratio is -11.87. In terms of profitability, LABP's ROE is -0.55%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, LABP is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs PTGX Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, PTGX has a market cap of 3.1B. Regarding current trading prices, LABP is priced at $22.93, while PTGX trades at $50.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas PTGX's P/E ratio is 63.74. In terms of profitability, LABP's ROE is -0.55%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, LABP is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs MLTX Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, MLTX has a market cap of 3B. Regarding current trading prices, LABP is priced at $22.93, while MLTX trades at $47.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas MLTX's P/E ratio is -20.27. In terms of profitability, LABP's ROE is -0.55%, compared to MLTX's ROE of -0.31%. Regarding short-term risk, LABP is less volatile compared to MLTX. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs IMVT Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, IMVT has a market cap of 2.9B. Regarding current trading prices, LABP is priced at $22.93, while IMVT trades at $17.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas IMVT's P/E ratio is -6.19. In terms of profitability, LABP's ROE is -0.55%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, LABP is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs MORF Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, LABP is priced at $22.93, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas MORF's P/E ratio is -14.88. In terms of profitability, LABP's ROE is -0.55%, compared to MORF's ROE of -0.22%. Regarding short-term risk, LABP is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for LABP.
LABP vs MOR Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, LABP is priced at $22.93, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas MOR's P/E ratio is -12.64. In terms of profitability, LABP's ROE is -0.55%, compared to MOR's ROE of -1.84%. Regarding short-term risk, LABP is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs KYMR Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, KYMR has a market cap of 2.8B. Regarding current trading prices, LABP is priced at $22.93, while KYMR trades at $44.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas KYMR's P/E ratio is -13.96. In terms of profitability, LABP's ROE is -0.55%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, LABP is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs CRNX Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, CRNX has a market cap of 2.8B. Regarding current trading prices, LABP is priced at $22.93, while CRNX trades at $30.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas CRNX's P/E ratio is -7.73. In terms of profitability, LABP's ROE is -0.55%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, LABP is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs KDNY Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, LABP is priced at $22.93, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas KDNY's P/E ratio is -12.47. In terms of profitability, LABP's ROE is -0.55%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, LABP is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for LABP.
LABP vs MYOV Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, LABP is priced at $22.93, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas MYOV's P/E ratio is -14.05. In terms of profitability, LABP's ROE is -0.55%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, LABP is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for LABP.
LABP vs CPRX Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, CPRX has a market cap of 2.5B. Regarding current trading prices, LABP is priced at $22.93, while CPRX trades at $21.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas CPRX's P/E ratio is 13.22. In terms of profitability, LABP's ROE is -0.55%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, LABP is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs MIRM Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, MIRM has a market cap of 2.5B. Regarding current trading prices, LABP is priced at $22.93, while MIRM trades at $51.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas MIRM's P/E ratio is -31.24. In terms of profitability, LABP's ROE is -0.55%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, LABP is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs NAMSW Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, NAMSW has a market cap of 2.5B. Regarding current trading prices, LABP is priced at $22.93, while NAMSW trades at $9.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas NAMSW's P/E ratio is N/A. In terms of profitability, LABP's ROE is -0.55%, compared to NAMSW's ROE of -0.33%. Regarding short-term risk, LABP is less volatile compared to NAMSW. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs ARWR Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, ARWR has a market cap of 2.4B. Regarding current trading prices, LABP is priced at $22.93, while ARWR trades at $17.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas ARWR's P/E ratio is -14.15. In terms of profitability, LABP's ROE is -0.55%, compared to ARWR's ROE of -0.47%. Regarding short-term risk, LABP is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs XENE Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, XENE has a market cap of 2.4B. Regarding current trading prices, LABP is priced at $22.93, while XENE trades at $32.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas XENE's P/E ratio is -9.76. In terms of profitability, LABP's ROE is -0.55%, compared to XENE's ROE of -0.32%. Regarding short-term risk, LABP is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs IBRX Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, IBRX has a market cap of 2.4B. Regarding current trading prices, LABP is priced at $22.93, while IBRX trades at $2.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas IBRX's P/E ratio is -4.76. In terms of profitability, LABP's ROE is -0.55%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, LABP is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs PRVB Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, LABP is priced at $22.93, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas PRVB's P/E ratio is -16.43. In terms of profitability, LABP's ROE is -0.55%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, LABP is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for LABP.
LABP vs LBPH Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, LABP is priced at $22.93, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas LBPH's P/E ratio is -26.66. In terms of profitability, LABP's ROE is -0.55%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, LABP is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for LABP.
LABP vs VAXX Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, VAXX has a market cap of 2.3B. Regarding current trading prices, LABP is priced at $22.93, while VAXX trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas VAXX's P/E ratio is -0.09. In terms of profitability, LABP's ROE is -0.55%, compared to VAXX's ROE of -0.00%. Regarding short-term risk, LABP is more volatile compared to VAXX. This indicates potentially higher risk in terms of short-term price fluctuations for LABP.
LABP vs DICE Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, LABP is priced at $22.93, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas DICE's P/E ratio is -21.91. In terms of profitability, LABP's ROE is -0.55%, compared to DICE's ROE of +0.56%. Regarding short-term risk, LABP is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for LABP.
LABP vs NAMS Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, NAMS has a market cap of 2.2B. Regarding current trading prices, LABP is priced at $22.93, while NAMS trades at $21.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas NAMS's P/E ratio is -10.89. In terms of profitability, LABP's ROE is -0.55%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, LABP is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs APLS Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, APLS has a market cap of 2.2B. Regarding current trading prices, LABP is priced at $22.93, while APLS trades at $18.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas APLS's P/E ratio is -9.94. In terms of profitability, LABP's ROE is -0.55%, compared to APLS's ROE of -1.00%. Regarding short-term risk, LABP is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs LGND Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, LGND has a market cap of 2.2B. Regarding current trading prices, LABP is priced at $22.93, while LGND trades at $121.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas LGND's P/E ratio is -15.80. In terms of profitability, LABP's ROE is -0.55%, compared to LGND's ROE of -0.16%. Regarding short-term risk, LABP is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs APGE Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, APGE has a market cap of 2.2B. Regarding current trading prices, LABP is priced at $22.93, while APGE trades at $37.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas APGE's P/E ratio is -10.08. In terms of profitability, LABP's ROE is -0.55%, compared to APGE's ROE of -0.19%. Regarding short-term risk, LABP is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs CALT Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, LABP is priced at $22.93, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas CALT's P/E ratio is -22.73. In terms of profitability, LABP's ROE is -0.55%, compared to CALT's ROE of -1.67%. Regarding short-term risk, LABP is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs RXRX Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, RXRX has a market cap of 2.1B. Regarding current trading prices, LABP is priced at $22.93, while RXRX trades at $5.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas RXRX's P/E ratio is -3.18. In terms of profitability, LABP's ROE is -0.55%, compared to RXRX's ROE of -0.75%. Regarding short-term risk, LABP is less volatile compared to RXRX. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs AGIO Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, AGIO has a market cap of 2.1B. Regarding current trading prices, LABP is priced at $22.93, while AGIO trades at $37.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas AGIO's P/E ratio is 3.14. In terms of profitability, LABP's ROE is -0.55%, compared to AGIO's ROE of +0.50%. Regarding short-term risk, LABP is less volatile compared to AGIO. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs DNLI Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, DNLI has a market cap of 2.1B. Regarding current trading prices, LABP is priced at $22.93, while DNLI trades at $14.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas DNLI's P/E ratio is -5.37. In terms of profitability, LABP's ROE is -0.55%, compared to DNLI's ROE of -0.36%. Regarding short-term risk, LABP is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs VCYT Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, VCYT has a market cap of 2.1B. Regarding current trading prices, LABP is priced at $22.93, while VCYT trades at $26.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas VCYT's P/E ratio is 63.29. In terms of profitability, LABP's ROE is -0.55%, compared to VCYT's ROE of +0.03%. Regarding short-term risk, LABP is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs BEAM Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, BEAM has a market cap of 2B. Regarding current trading prices, LABP is priced at $22.93, while BEAM trades at $21.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas BEAM's P/E ratio is -4.40. In terms of profitability, LABP's ROE is -0.55%, compared to BEAM's ROE of -0.44%. Regarding short-term risk, LABP is less volatile compared to BEAM. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs VCEL Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, VCEL has a market cap of 2B. Regarding current trading prices, LABP is priced at $22.93, while VCEL trades at $40.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas VCEL's P/E ratio is 803.40. In terms of profitability, LABP's ROE is -0.55%, compared to VCEL's ROE of +0.01%. Regarding short-term risk, LABP is less volatile compared to VCEL. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.
LABP vs KNSA Comparison
LABP plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LABP stands at 71.7M. In comparison, KNSA has a market cap of 2B. Regarding current trading prices, LABP is priced at $22.93, while KNSA trades at $28.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LABP currently has a P/E ratio of -5.73, whereas KNSA's P/E ratio is -113.38. In terms of profitability, LABP's ROE is -0.55%, compared to KNSA's ROE of -0.04%. Regarding short-term risk, LABP is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for LABP.